echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Amgen has reached two deals with more than $3 billion to strengthen its R & D pipeline

    Amgen has reached two deals with more than $3 billion to strengthen its R & D pipeline

    • Last Update: 2015-09-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Xinkangjie / xiaohanqing acquired dezima Pharma, a Dutch biotechnology company, on September 22, 2015, to add weight to its research and development pipeline of cardiovascular diseases At the same time, it is striving to reach cooperation intention with xencor, a cancer immunotherapy company, on tumor and inflammatory drugs, and jointly develop bispecific antibodies The main chip of CETP inhibitor ta-8995 Dutch biotechnology company dezima is an oral active cholesterol inhibitor called ta-8995, which has shown great potential in phase II clinical trials Amgen, the US pharmaceutical giant, paid US $300 million in advance for the acquisition of dezima and gained control of dezima's cardiovascular drugs Dezima's shareholders will also receive potential milestone payments totalling $1.25 billion The data of phase IIB clinical trials published earlier this year showed that ta-8995 could reduce LDL-C by 45% - 48% compared with the baseline level, either alone or in combination with statins Ta-8995 is a CETP inhibitor, which belongs to the same category as evacetrapib of Lilly, anacetrapib of mosadon and bms-795311 of Bristol Myers Squibb / Simcere These drugs are currently in the late stage of development Amgen has incorporated dezima's cardiovascular disease drug ta-8995 into its R & D pipeline and added an oral cardiovascular drug, which is complementary to the recently approved injectable cholesterol drug repatha (evolocumab) of Amgen Amgen will go hand in hand with its competitors Sanofi and its regenerator drug praluent (alirocumab) to compete in the cardiovascular market While acquiring dezima Pharma, a Dutch biotech company, to expand its cardiovascular field, Amgen has also launched cooperation with xencor, a cancer immunotherapy company, covering six antibody projects Amgen paid xencor $45 million in advance and $1.7 billion in milestone payments Bispecific antibody can combine two different antigens at the same time, it has many characteristics, for example, it can combine to target tumor cells, it can also combine with immune cells, increase the immune response of patients to cancer Bispecific antibody is a kind of genetically engineered antibody, which has become a hot spot in the field of antibody engineering and has a broad application prospect in the immunotherapy of tumor In the agreement between Amgen and xencor, xencor will use the expertise of molecular engineering to develop the bispecific antibody molecules determined in Amgen's R & D plan for five targets Amgen has its own bispecific antibody project bite, and has developed the first drug blincyto (blinatumomab) for the treatment of acute lymphoblastic leukemia, which was launched earlier this year.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.